Trading Signals: TGTX Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 14, 2022)(TG Therapeutics Inc)
| TGTX latest price $17.8800 (-4.54%) ($17.1600 - $18.6800) on Wed. Jun. 3, 2020. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 8.72% (three month average) | RSI | 39 | Latest Price | $17.8800(-4.54%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | TGTX declines -2.8% a day on average for past five trading days. | Weekly Trend | TGTX declines -3% a week on average for past two weeks. | Market Behavior | Value stock rally for large cap. Broad based rally for small cap. | Correlated ETFs | Broad market will support TGTX advance at 0% a week (0% probability) XBI(64%) ARKG(59%) ARKK(56%) IWO(55%) IBB(54%) | Factors Impacting TGTX price | TGTX will decline at least -4.36% in a week (0% probabilities). VIXM(-34%) VXX(-32%) UUP(-17%) DRIV(-3%) TBT(-2%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -4.36% (StdDev 8.72%) | Hourly BBV | 0 () | Intraday Trend | -3.9% | | | |
|
Resistance Level | $19.66 | 5 Day Moving Average | $18.68(-4.28%) | 10 Day Moving Average | $19.73(-9.38%) | 20 Day Moving Average | $19.66(-9.05%) | To recent high | -18.1% | To recent low | 150.4% | Market Cap | $2.264b | | | | TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY. |